Drug class
Selective fibroblast growth factor receptor (FGFR) kinase inhibitor; targeted antineoplastic agent
Mechanism of action
Lirafugratinib is an oral, selective FGFR inhibitor that targets FGFR2 alterations driving tumour growth. It inhibits FGFR2 kinase signalling, reducing downstream pathway activation in FGFR2 fusion- or rearrangement-positive cholangiocarcinoma. The product label describes it as a kinase inhibitor.
General use cases
- Treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harbouring an FGFR2 gene fusion or other rearrangement, under the US LYRFIGTU product label (approved September 23, 2026).
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
